208 related articles for article (PubMed ID: 19459850)
1. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer.
Kono K; Mizukami Y; Daigo Y; Takano A; Masuda K; Yoshida K; Tsunoda T; Kawaguchi Y; Nakamura Y; Fujii H
Cancer Sci; 2009 Aug; 100(8):1502-9. PubMed ID: 19459850
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma.
Iwahashi M; Katsuda M; Nakamori M; Nakamura M; Naka T; Ojima T; Iida T; Yamaue H
Cancer Sci; 2010 Dec; 101(12):2510-7. PubMed ID: 20874827
[TBL] [Abstract][Full Text] [Related]
3. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma.
Mizukami Y; Kono K; Daigo Y; Takano A; Tsunoda T; Kawaguchi Y; Nakamura Y; Fujii H
Cancer Sci; 2008 Jul; 99(7):1448-54. PubMed ID: 18452554
[TBL] [Abstract][Full Text] [Related]
4. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy.
Suda T; Tsunoda T; Daigo Y; Nakamura Y; Tahara H
Cancer Sci; 2007 Nov; 98(11):1803-8. PubMed ID: 17784873
[TBL] [Abstract][Full Text] [Related]
5. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.
Kono K; Iinuma H; Akutsu Y; Tanaka H; Hayashi N; Uchikado Y; Noguchi T; Fujii H; Okinaka K; Fukushima R; Matsubara H; Ohira M; Baba H; Natsugoe S; Kitano S; Takeda K; Yoshida K; Tsunoda T; Nakamura Y
J Transl Med; 2012 Jul; 10():141. PubMed ID: 22776426
[TBL] [Abstract][Full Text] [Related]
6. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
[TBL] [Abstract][Full Text] [Related]
8. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer.
Suzuki H; Fukuhara M; Yamaura T; Mutoh S; Okabe N; Yaginuma H; Hasegawa T; Yonechi A; Osugi J; Hoshino M; Kimura T; Higuchi M; Shio Y; Ise K; Takeda K; Gotoh M
J Transl Med; 2013 Apr; 11():97. PubMed ID: 23578144
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S
Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients.
Iinuma H; Fukushima R; Inaba T; Tamura J; Inoue T; Ogawa E; Horikawa M; Ikeda Y; Matsutani N; Takeda K; Yoshida K; Tsunoda T; Ikeda T; Nakamura Y; Okinaga K
J Transl Med; 2014 Apr; 12():84. PubMed ID: 24708624
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
Murahashi M; Hijikata Y; Yamada K; Tanaka Y; Kishimoto J; Inoue H; Marumoto T; Takahashi A; Okazaki T; Takeda K; Hirakawa M; Fujii H; Okano S; Morita M; Baba E; Mizumoto K; Maehara Y; Tanaka M; Akashi K; Nakanishi Y; Yoshida K; Tsunoda T; Tamura K; Nakamura Y; Tani K
Clin Immunol; 2016 May; 166-167():48-58. PubMed ID: 27072896
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.
Hazama S; Nakamura Y; Takenouchi H; Suzuki N; Tsunedomi R; Inoue Y; Tokuhisa Y; Iizuka N; Yoshino S; Takeda K; Shinozaki H; Kamiya A; Furukawa H; Oka M
J Transl Med; 2014 Mar; 12():63. PubMed ID: 24612787
[TBL] [Abstract][Full Text] [Related]
15. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.
Takahashi R; Toh U; Iwakuma N; Takenaka M; Otsuka H; Furukawa M; Fujii T; Seki N; Kawahara A; Kage M; Matsueda S; Akagi Y; Yamada A; Itoh K; Sasada T
Breast Cancer Res; 2014 Jul; 16(4):R70. PubMed ID: 24992895
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer.
Ishikawa H; Imano M; Shiraishi O; Yasuda A; Peng YF; Shinkai M; Yasuda T; Imamoto H; Shiozaki H
Gastric Cancer; 2014 Jan; 17(1):173-80. PubMed ID: 23613128
[TBL] [Abstract][Full Text] [Related]
17. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients.
Mine T; Gouhara R; Hida N; Imai N; Azuma K; Rikimaru T; Katagiri K; Nishikori M; Sukehiro A; Nakagawa M; Yamada A; Aizawa H; Shirouzu K; Itoh K; Yamana H
Cancer Sci; 2003 Jun; 94(6):548-56. PubMed ID: 12824881
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.
Yoshitake Y; Fukuma D; Yuno A; Hirayama M; Nakayama H; Tanaka T; Nagata M; Takamune Y; Kawahara K; Nakagawa Y; Yoshida R; Hirosue A; Ogi H; Hiraki A; Jono H; Hamada A; Yoshida K; Nishimura Y; Nakamura Y; Shinohara M
Clin Cancer Res; 2015 Jan; 21(2):312-21. PubMed ID: 25391695
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
Meneveau MO; Petroni GR; Salerno EP; Lynch KT; Smolkin M; Woodson E; Chianese-Bullock KA; Olson WC; Deacon D; Patterson JW; Grosh WW; Slingluff CL
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035112
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.
Baba T; Sato-Matsushita M; Kanamoto A; Itoh A; Oyaizu N; Inoue Y; Kawakami Y; Tahara H
J Transl Med; 2010 Sep; 8():84. PubMed ID: 20843377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
